Compare Medpace Holdings Inc (MEDP) vs Redwire Corporation (RDW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Redwire Corporation — how do they compare? Medpace Holdings Inc trades at $612.05 (market cap $16.82B), while Redwire Corporation trades at $9.58 (market cap $2.44B). The key difference: Medpace Holdings Inc is far larger — about 6.9× Redwire Corporation's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Redwire Corporation nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Redwire Corporation for 18 Days on average.
| MEDP | RDW | |
|---|---|---|
Market Cap | $16.82B | $2.44B |
Volume | 223,093 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $630.19 | $25.90 |
52-Week Low | $393.42 | $5.06 |
Typical Hold Time | 14 Days | 18 Days |
Enterprise Value | $16.44B | $1.97B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $612.05, up 1.29% today, near its consensus price target of $620.44. The stock shows strong profitability with a 17.67% net margin and has beaten earnings estimates for the last three quarters. Technical indicators are neutral overall, with support at $595 and resistance at $612. Recent news highlights CEO stock sales and institutional position changes, while the company prepares to report Q3 2026 results on October 21.
Outlook remains positive given consistent earnings beats and projected revenue growth to $2.8B in 2026. Risks include high valuation multiples (P/E 35.41) and insider selling. Analyst consensus is cautious with 79% hold ratings, suggesting limited near-term upside but solid fundamental support for long-term holders.
RDW trades at $9.58, down 6.45% today, with technical indicators showing bearish momentum despite oversold RSI readings near 27. The company reported significant losses with a -57.26% net income margin and negative cash flow from operations, though revenue grew to $335M in 2025. Recent Space Force contract wins and partnerships highlight growth potential in defense and space infrastructure markets.
While analyst consensus remains bullish with an 80% buy rating and $14.88 price target, RDW faces substantial execution risks from persistent losses and dependence on SpaceX's Starship success. The stock offers high-risk exposure to the growing space economy but requires careful monitoring of profitability improvements and contract execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Redwire Corporation
Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →
